Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: Results from the I-MOVE multicentre case-control study

Eurosurveillance

Volumn 18, Issue 5, 2013, Pages

  Kissling, E ^a   Valenciano, M ^a   Larrauri, A ^b   Oroszi, B ^c   Cohen, J M ^d   Nunes, B ^e   Pitigoi, D ^f,g   Rizzo, C ^h   Rebolledo, J ^i,j   Paradowska Stankiewicz, I ^k   Jimenez Jorge S ^b   Horvath J K ^c   Daviaud, I ^d   Guiomar, R ^e   Necula, G ^f   Bella, A ^h   O'Donnell, J ⁱ   Gluchowska M ^k   Ciancio, B C ^j   Nicoll, A ^j   Moren, A ^a   more..

^a EPICONCEPT   (France)

^b CARLOS III INSTITUTE OF HEALTH   (Spain)

^c Office of the Chief Medical Officer   (Hungary)

^d GROG/Open Rome   (France)

^e NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^f NATIONAL INSTITUTE FOR RESEARCH AND DEVELOPMENT IN MICROTECHNOLOGIES   (Romania)

^g CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^h ISTITUTO SUPERIORE DI SANITÀ   (Italy)

ⁱ HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

^j EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^k NATIONAL MEDICINES INSTITUTE   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DRUG EFFECT; EUROPE; FEMALE; HUMAN; INFANT; INFLUENZA A; INFLUENZA VIRUS A H3N2; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEWBORN; NOSE SMEAR; PATIENT INFORMATION; PRESCHOOL CHILD; QUESTIONNAIRE; RESPIRATORY TRACT INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE SIZE; SEASONAL INFLUENZA; VACCINATION; VIRUS DETECTION;

EID: 84873314436     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/ese.18.05.20390-en     Document Type: Article

References (43)

1. Mereckiene J, Cotter S, D'Ancona F, Giambi C, Nicoll A, Levy-Bruhl D, et al. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Euro Surveill. 2010;15(44). pii=19700. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19700
2. Valenciano M, Ciancio B, Moren A. First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States. Euro Surveill. 2008;13(43). pii=19015. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19015
3. I-MOVE in Europe. I-MOVE in Europe. [Accessed 1 Aug 2012]. Available from: https://sites.google.com/site/epiflu/
4. Kissling E, Valenciano M, Falcao J, Larrauri A, Widgren K, Pitigoi D, et al. "I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9. Euro Surveill. 2009;14(44). pii=19388. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19388
5. Valenciano M, Kissling E, Cohen J-M, Oroszi B, Barret A-S, Rizzo C, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 2011;8(1):e1000388.
6. Kissling E, Valenciano M. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. Euro Surveill. 2011;16(11). pii=20146. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19818
7. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret A-S, Rizzo C, et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS ONE. 2011;6(11):e27622.
8. Kissling E, Valenciano M. Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: results from the I-MOVE multicentre case-control study, 2011/12. Euro Surveill. 2012;17(15). pii=20146. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20146
9. European Centre for Disease Prevention and Control (ECDC). Protocol for case-control studies to measure influenza vaccine effectiveness in the European Union and European Economic Area Member States. Stockholm:ECDC; 2009. Available from:http://ecdc.europa.eu/en/publications/publications/0907_ted_influenza_ah1n1_measuring_influenza_vaccine_effectiveness_protocol_case_control_studies.pdf
10. Orszagos Epidemiológiai Központ (OEK). Az Országos Epidemiológiai Központ módszertani level a 2011. évi védõoltásokról [The National Centre for Epidemiology methodological letter of the year 2011 on vaccinations]. Epinfo 2011;18. 21 Feb 2011. Hungarian. Available from: http://www.oek.hu/oek.web?nid=444&pid=1
11. Institut de Veille Sanitaire (InVS) Le calendrier vaccinal et les recommandations vaccinales 201 selon l'avis du Haut Conseil de la Santé Publique. [2011 vaccination schedule and recommendations from the Haut Conseil de la Santé Publique in France]. BEH 10-11/2011 p. 103-20. French. Available from:http://www.invs.sante.fr/content/download/4393/28810/version/4/file/beh_10_11_2011.pdf
12. Ministerio de Sanidad, Servicios Sociales e Igualdad (MSPS). Prevención de la gripe. Vacunación antigripal [Influenza prevention. Recommendations for influenza vaccination]. [Accessed Jul 4 2012]. Spanish. Available from: http://www.msps.es/ciudadanos/enfLesiones/enfTransmisibles/gripe/gripe.htm#prevencion
13. Ministerio della Salute. Prevenzione e controllo dell'influenza: raccomandazioni per la stagione 2011-2012. [Prevention and control of influenza: recommendations for the season 2011-2012]. Roma: Ministero della Salute; 2012. Italian. Available from: http://www.normativasanitaria.it/normsan-pdf/0000/39451_1.pdf
14. Metodologia de supraveghere a gripei, infectiilor acute respiratorii şi SARI pentru sezonul 2011-2012. [Methodology of surveillance of influenza, acute respiratory infections and SARI, season 2011-2012] Bucarest: National Centre for Surveillance and Control of Communicable Diseases; 2012. Romanian. Available from:http://www.insp.gov.ro/cnscbt/index.php?option=com_docman&task=doc_download&gid=286&Itemid=10
15. Vacinaçao contra a gripe com a vacina trivalente na época 2011/2012-Alargamento dos groupos de risco para vacinaçao gratuita. [Influenza vaccination with the trivalent vaccine in the season 2011/2012-Extension of risk groups for free vaccinations] Lisbon: Directorate General of Health; Sep 2011. Portuguese. Available from:http://www.dgs.pt/ms/2/default.aspx?id=5509
16. Program Szczepień Ochronnych na rok 2012. [Immunisation Programme for 2012] Warsaw: Chief Sanitary Inspectorate; 2011. Polish. Available from:http://www.pis.gov.pl/userfiles/file/Departament%20EP/szczepienia/zal_szczep%20PSO%202012.pdf
17. Target groups for seasonal influenza vaccine 2011/2012-Ireland. Dublin: Health Protection Surveillance Centre; 2011. Available from:. http://www.immunisation.ie/en/HealthcareProfessionals/Correspondence/PDFFile_16872_en.pdf
18. European Centre for Disease Control and Prevention (ECDC). Community Network of Reference Laboratories (CNRL) for Human Influenza in Europe. Influenza virus characterisation, summary Europe, June 2012 Stockholm:ECDC; 2012. Available from: http://www.ecdc.europa.eu/en/publications/Publications/Influenza-visus-characterisation-June-2012.pdf
19. European Centre for Disease Control and Prevention (ECDC). European Influenza Surveillance Network (EISN). [Accessed 5 Jul 2012]. Available from:http://www.ecdc.europa.eu/en/activities/surveillance/eisn/pages/index.aspx
20. European Commission. Commission Decision 2009/363/EC of 30 April 2009 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. OJ L 110, 1.5.2009 p. 58. Available from:http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:110:0058:0059:EN:PDF
21. European Centre for Disease Control and Prevention (ECDC). Laboratory surveillance of influenza: Table [Accessed 5 Jul 2012]. Available from:http://www.ecdc.europa.eu/en/activities/surveillance/EISN/laboratory_network/Pages/laboratory_surveillance_influenza.aspx
22. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006 Jun;11(2):193-206.
23. European Centre for Disease Control and Prevention (ECDC). Weekly Influenza Surveillance Overview (WISO). Stockholm:ECDC; 2012 [Accessed 4 Jul 2012]. Available from:http://ecdc.europa.eu/en/publications/surveillance_reports/influenza/Pages/weekly_influenza_surveillance_overview.aspx
24. Cheng AC, Kotsimbos T, Kelly HA, Irving LB, Bowler SD, Brown SG, et al. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: a test-negative case control study. Vaccine. 2011;29(43):7320-5.
25. Hellenbrand W, Jorgensen P, Schweiger B, Falkenhorst G, Nachtnebel M, Greutélaers B, et al. Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controls. BMC Infectious Dis. 2012;12(1):127.
26. Belongia EA, Kieke BA, Donahue JG, Coleman LA, Irving SA, Meece JK, et al. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results. Vaccine. 2011;29(38):6558-63.
27. Andrews N, Waight P, Yung C-F, Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis. 2011;203(1):32-9.
28. Caviness AC, Demmler GJ, Selwyn BJ. Clinical and laboratory features of neonatal herpes simplex virus infection: a case-control study. Pediatr Infect Dis J. 2008;27(5):425-30.
29. Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, Fonseca K, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis. 2009;199(2):168-79.
30. Castilla J, Beristain X, Martínez-Artola V, Navascués A, García Cenoz M, Alvarez N, et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. Vaccine. 2012;30(3):539-43.
31. Fleming DM, Andrews NJ, Ellis JS, Bermingham A, Sebastianpillai P, Elliot AJ, et al. Estimating influenza vaccine effectiveness using routinely collected laboratory data. J Epidemiol Community Health. 2010;64(12):1062-7.
32. Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vázquez M. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis. 2010;51(12):1355-61.
33. Valenciano M, Kissling E, Ciancio BC, Moren A. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine. 2010;28(46):7381-8.
34. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis. 2009;199(2):159-67.
35. Centers for Disease Control and Prevention (CDC). Prevention and Control of Influenza-Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2005;54(RR08). p. 1-40. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5408a1.htm
36. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis. 1995;172(5):1352-5.
37. Martínez-Baz I, Reina G, Martínez-Artola V, Fernández-Alonso M, Salcedo E, Mazón A, et al. [Effect of the time between symptom onset, swabbing and testing on the detection of influenza virus]. Enferm Infecc Microbiol Clin. 2012;30(1):11-4.
38. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167(7):775-85.
39. World Health Organisation (WHO). Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. Geneva: WHO;Feb 2012. Available from:http://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf
40. Yao X, Hamilton RG, Weng N, Xue Q-L, Bream JH, Li H, et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine. 2011;29(31):5015-21.
41. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine. 2006;24(8):1159-69.
42. Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, et al. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine. 2010;28(23):3929-35.
43. McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol. 2009;21(4):418-24.